ORIC PHARMACEUTICALS, INC. (ORIC) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$45.30M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$39.62M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$36.67M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$39.06M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$45.30M | (m) | (m) | (m) | $356.00K* | -$31.61M* | (m) | (m) | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$39.62M | (m) | (m) | (m) | $2.00K | -$32.44M | (m) | (m) | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$36.67M | (m) | (m) | (m) | $35.00K* | -$25.11M* | (m) | (m) | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$39.06M | (m) | (m) | (m) | $63.00K* | -$30.84M* | (m) | (m) | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$32.72M | (m) | (m) | (m) | $387.00K | -$32.53M | (m) | (m) | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$38.32M | (m) | (m) | (m) | $418.00K* | -$28.80M* | (m) | (m) | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$36.02M | (m) | (m) | (m) | $333.00K* | -$25.63M* | (m) | (m) | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$28.99M | (m) | (m) | (m) | $218.00K | -$30.19M | (m) | (m) | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$28.68M | (m) | (m) | (m) | $77.00K* | -$19.64M* | (m) | (m) | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$24.99M | (m) | (m) | (m) | $405.00K* | -$21.14M* | (m) | (m) | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$25.68M | (m) | (m) | (m) | $310.00K | -$20.63M | (m) | (m) | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$25.69M | (m) | (m) | (m) | $401.00K* | -$19.32M* | (m) | (m) | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$20.70M | (m) | (m) | (m) | $667.00K* | -$17.78M* | (m) | (m) | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$23.26M | (m) | (m) | (m) | $723.00K | -$22.72M | (m) | (m) | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$18.46M | (m) | (m) | (m) | $233.00K* | -$12.14M* | (m) | (m) | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$21.06M | (m) | (m) | (m) | $135.00K* | -$16.21M* | (m) | (m) | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$16.55M | (m) | (m) | (m) | $182.00K | -$14.90M | (m) | (m) | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$25.60M | (m) | (m) | (m) | $50.00K* | -$9.58M* | (m) | (m) | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$11.12M | (m) | (m) | (m) | $202.00K* | -$9.58M* | (m) | $7.72M | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$9.18M | (m) | (m) | (m) | $4.00K | -$8.28M | (m) | $7.25M | (m) | $0.00 |
| 2019-09-30 | Reported | (m) | -$7.10M | (m) | (m) | (m) | $219.00K* | -$5.36M* | (m) | (m) | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$6.36M | (m) | (m) | (m) | $393.00K* | -$5.49M* | (m) | $5.04M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$6.35M | (m) | (m) | (m) | $100.00K | -$5.53M | (m) | $5.21M | (m) | $0.00 |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$143.00M | (m) | (m) | (m) | $712.00K | -$110.97M | (m) | (m) | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$142.90M | (m) | (m) | (m) | $1.19M | -$112.66M | (m) | (m) | (m) | $0.00 |
| 2023-12-31 | Reported | (m) | -$110.78M | (m) | (m) | (m) | $849.00K | -$85.69M | (m) | (m) | (m) | $0.00 |
| 2022-12-31 | Reported | (m) | -$91.77M | (m) | (m) | (m) | $2.08M | -$75.14M | (m) | (m) | (m) | $0.00 |
| 2021-12-31 | Reported | (m) | -$78.87M | (m) | (m) | (m) | $939.00K | -$59.54M | (m) | (m) | (m) | $0.00 |
| 2020-12-31 | Reported | (m) | -$74.19M | (m) | (m) | (m) | $667.00K | -$45.27M | (m) | (m) | (m) | $0.00 |
| 2019-12-31 | Reported | (m) | -$28.57M | (m) | (m) | (m) | $768.00K | -$23.53M | (m) | (m) | (m) | $0.00 |
| 2018-12-31 | Reported | (m) | -$22.37M | (m) | (m) | (m) | $525.00K | -$20.68M | (m) | (m) | (m) | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |